Teladoc Health Adds GLP-1 Self-Pay Option to Comprehensive Weight Care
Teladoc Health (NYSE: TDOC) has announced a pharmacy integration partnership with Gifthealth, Eli Lilly's LillyDirect pharmacy partner, to provide self-pay access to FDA-approved Zepbound® (tirzepatide) for members enrolled in its Comprehensive Weight Care Program who lack GLP-1 insurance coverage.
The integration will enable eligible Teladoc Health members to receive prescribed Zepbound® directly at home, with the company's care teams maintaining full visibility of the fulfillment process. The program includes:
- Multi-disciplinary support from licensed clinicians trained in obesity medicine
- Access to registered dietitians and health coaches
- A connected digital scale
- Personalized lifestyle coaching
- Nutrition counseling
- Mental health support
- Behavior change resources
Teladoc Health (NYSE: TDOC) ha annunciato una partnership per l'integrazione della farmacia con Gifthealth, partner della farmacia LillyDirect di Eli Lilly, per fornire accesso a pagamento diretto al Zepbound® (tirzepatide) approvato dalla FDA per i membri iscritti al suo Programma Completo di Cura del Peso che non hanno copertura assicurativa per GLP-1.
L'integrazione permetterà ai membri idonei di Teladoc Health di ricevere il Zepbound® prescritto direttamente a casa, con i team di assistenza dell'azienda che mantengono piena visibilità del processo di adempimento. Il programma include:
- Supporto multidisciplinare da parte di clinici autorizzati specializzati in medicina dell'obesità
- Accesso a dietisti registrati e coach della salute
- Una bilancia digitale connessa
- Coaching personalizzato per uno stile di vita sano
- Consulenza nutrizionale
- Supporto per la salute mentale
- Risorse per il cambiamento comportamentale
Teladoc Health (NYSE: TDOC) ha anunciado una asociación de integración farmacéutica con Gifthealth, el socio farmacéutico LillyDirect de Eli Lilly, para proporcionar acceso de pago directo al Zepbound® (tirzepatide) aprobado por la FDA para los miembros inscritos en su Programa Integral de Cuidado del Peso que carecen de cobertura de seguro para GLP-1.
La integración permitirá a los miembros elegibles de Teladoc Health recibir el Zepbound® recetado directamente en casa, con los equipos de atención de la empresa manteniendo plena visibilidad del proceso de cumplimiento. El programa incluye:
- Apoyo multidisciplinario de clínicos licenciados capacitados en medicina de la obesidad
- Acceso a dietistas registrados y entrenadores de salud
- Una balanza digital conectada
- Coaching personalizado para un estilo de vida saludable
- Asesoramiento nutricional
- Apoyo en salud mental
- Recursos para el cambio de comportamiento
텔라도크 헬스 (NYSE: TDOC)는 엘리 릴리의 릴리다이렉트 약국 파트너인 기프트헬스와 제약 통합 파트너십을 발표하여 GLP-1 보험 보장이 없는 포괄적 체중 관리 프로그램에 등록된 회원들에게 FDA 승인된 제프바운드® (티르제파타이드)에 대한 자가 지불 접근을 제공합니다.
이 통합을 통해 자격이 있는 텔라도크 헬스 회원들은 처방된 제프바운드를 집에서 직접 받을 수 있으며, 회사의 케어 팀은 이행 과정의 전체 가시성을 유지합니다. 이 프로그램에는 다음이 포함됩니다:
- 비만 의학에 교육받은 면허가 있는 임상의의 다학제 지원
- 등록된 영양사 및 건강 코치에 대한 접근
- 연결된 디지털 체중계
- 개인화된 라이프스타일 코칭
- 영양 상담
- 정신 건강 지원
- 행동 변화 리소스
Teladoc Health (NYSE: TDOC) a annoncé un partenariat d'intégration pharmaceutique avec Gifthealth, le partenaire de pharmacie LillyDirect d'Eli Lilly, pour fournir un accès en paiement direct au Zepbound® (tirzepatide) approuvé par la FDA pour les membres inscrits dans son Programme Complet de Soins du Poids qui n'ont pas de couverture d'assurance pour le GLP-1.
L'intégration permettra aux membres éligibles de Teladoc Health de recevoir le Zepbound® prescrit directement à domicile, avec les équipes de soins de l'entreprise maintenant une pleine visibilité sur le processus d'exécution. Le programme comprend :
- Un soutien multidisciplinaire de cliniciens agréés formés en médecine de l'obésité
- Accès à des diététiciens enregistrés et à des coachs santé
- Une balance numérique connectée
- Un coaching de style de vie personnalisé
- Conseils nutritionnels
- Soutien en santé mentale
- Ressources pour le changement de comportement
Teladoc Health (NYSE: TDOC) hat eine Partnerschaft zur Integration einer Apotheke mit Gifthealth, dem LillyDirect-Apothekenpartner von Eli Lilly, angekündigt, um Selbstzahlern Zugang zu dem von der FDA zugelassenen Zepbound® (Tirzepatid) für Mitglieder zu ermöglichen, die im Rahmen seines umfassenden Gewichtsmanagementprogramms keine GLP-1-Versicherung haben.
Die Integration ermöglicht es berechtigten Mitgliedern von Teladoc Health, das verschriebene Zepbound® direkt nach Hause zu erhalten, während die Pflege-Teams des Unternehmens die volle Transparenz des Erfüllungsprozesses aufrechterhalten. Das Programm umfasst:
- Multidisziplinäre Unterstützung durch lizenzierte Fachkräfte, die in der Adipositasmedizin geschult sind
- Zugang zu registrierten Diätassistenten und Gesundheitscoaches
- Eine verbundene digitale Waage
- Personalisierte Lebensstilberatung
- Ernährungsberatung
- Unterstützung für psychische Gesundheit
- Ressourcen für Verhaltensänderungen
- New revenue stream through self-pay GLP-1 medication option
- Enhanced service offering with end-to-end weight management program
- Strategic partnership with major pharmaceutical company (Eli Lilly)
- Improved competitive position in weight care market
- Potential margin pressure from self-pay pricing competition
- Dependency on third-party pharmacy fulfillment
Insights
Teladoc's strategic partnership with Gifthealth to integrate Eli Lilly's Zepbound (tirzepatide) into its Comprehensive Weight Care Program represents a significant expansion of its obesity treatment capabilities. By offering a self-pay option for members without GLP-1 insurance coverage, Teladoc addresses a critical market gap while positioning itself as a more comprehensive virtual healthcare provider.
This integration creates a complete care ecosystem that includes medication access, monitoring, and supportive care elements (coaching, nutrition counseling, mental health support). Most importantly, it establishes Teladoc as a key distribution channel in the rapidly growing GLP-1 market, potentially driving new member acquisition and retention.
The move allows Teladoc to differentiate from competitors by emphasizing FDA-approved medications versus compounded alternatives, aligning with the company's clinical credibility. For investors, this represents a strategic pivot toward higher-value care offerings in a category experiencing explosive growth.
The partnership demonstrates Teladoc's ability to build relationships with major pharmaceutical players like Eli Lilly, potentially opening doors for future collaborations. While financial terms aren't disclosed, this development could strengthen Teladoc's value proposition to both individual members and enterprise clients (employers and health plans) seeking comprehensive obesity management solutions.
This partnership represents a potentially significant revenue opportunity for Teladoc in the rapidly expanding GLP-1 weight management market. By integrating with Lilly's pharmacy network, Teladoc creates a new revenue path through its Comprehensive Weight Care Program while addressing the substantial market of patients lacking insurance coverage for these medications.
The integration establishes Teladoc as a full-service provider in the weight management ecosystem - from initial consultation through prescription, fulfillment monitoring, and ongoing care support. This vertical integration model could improve patient adherence, outcomes, and ultimately retention.
From a competitive standpoint, Teladoc's emphasis on FDA-approved medications versus compounded alternatives positions the company as a premium provider focused on safety and efficacy. This approach may attract quality-conscious consumers and enterprise clients concerned about liability.
While no specific pricing details were provided, this move leverages Teladoc's existing infrastructure and clinical staff while adding a potentially high-margin medication component. The company can now capture more value from the same patient interaction by facilitating both the consultation and medication fulfillment process.
This strategic expansion into weight management with pharmaceutical partnerships demonstrates Teladoc's focus on diversifying beyond traditional telehealth into specialized, high-value care verticals that address chronic conditions with substantial market demand.
Pharmacy Integration with Gifthealth to Extend Seamless Support for FDA-Approved Medication to Obesity Program Members Without GLP-1 Coverage
PURCHASE, NY, March 06, 2025 (GLOBE NEWSWIRE) -- Teladoc Health (NYSE: TDOC) today announced a pharmacy integration agreement with Eli Lilly’s LillyDirect pharmacy partner, Gifthealth, which will help streamline access to FDA-approved Zepbound® (tirzepatide) for Teladoc Health members enrolled in its Comprehensive Weight Care Program. This option will help members without insurance coverage for GLP-1s for obesity have more seamless access to affordable, safe, and effective medicine.
LillyDirect is Eli Lilly and Company’s direct-to-consumer digital healthcare platform. Eligible Teladoc Health members, if prescribed Zepbound® by their Teladoc Health provider for an on-label indication, can have single-use Zepbound® vials delivered directly to their home. Teladoc Health’s Comprehensive Weight Care and Primary360 teams will have full visibility into each stage of the patient’s Zepbound® fulfillment journey—from dispensing to shipping to delivery to refills.
“At Teladoc Health, we are dedicated to expanding access to clinically responsible, evidence-based care,” said Kelly Bliss, President, U.S. Group Health at Teladoc Health. “We provide the integrated support necessary for patient safety and sustainable health outcomes. By integrating with LillyDirect, we are reducing barriers to high-quality care and helping our members afford transformative FDA-approved treatments while avoiding the potential risks of compounded medications recently offered by others.”
In addition to clinically appropriate medication access, members enrolled in the Teladoc Health Comprehensive Weight Care Program have multi-disciplinary, evidence-based care and support from licensed clinicians who have additional training in obesity medicine, registered dietitians, and expert health coaches. Members receive a connected digital scale, personalized lifestyle coaching, nutrition counseling, mental health support, and proven behavior change resources to help people manage and maintain a healthy weight. Teladoc Health’s end-to-end programs drive high levels of health engagement and meaningful, sustained outcomes for members taking GLP-1 medications.
“At Gifthealth, we are excited to integrate with Teladoc Health to streamline access to Zepbound® for patients in need. Through Gifthealth’s relationship with LillyDirect, we provide a seamless, affordable path for patients to receive this FDA-approved treatment. Our technology-powered solutions aim to remove barriers, improve medication access, and ensure that patients have reliable access to safe and effective weight management treatments,” said Robert Hoppe, EVP of Life Sciences at Gifthealth.
Pricing information is available at LillyDirect®.
About Teladoc Health
Teladoc Health empowers all people everywhere to live their healthiest lives by transforming the healthcare experience. As the world leader in virtual care, Teladoc Health uses proprietary health signals and personalized interactions to drive better health outcomes across the full continuum of care, at every stage in a person’s health journey. Teladoc Health leverages more than two decades of expertise and data-driven insights to meet the growing virtual care needs of consumers and healthcare professionals. For more information, please visit www.teladochealth.com.
Media:
Lou Serio
PR@teladochealth.com
FAQ
What does Teladoc's partnership with Gifthealth mean for TDOC members seeking weight loss medication?
What services are included in Teladoc's Comprehensive Weight Care Program with GLP-1 medications?
How will TDOC's integration with LillyDirect improve medication management?
What advantages does TDOC's Zepbound® distribution offer over compound medications?
